http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014105496-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0642 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2014-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014105496-A |
| titleOfInvention | WAYS TO REDUCE THE NUMBER OF EOSINOPHILS |
| abstract | 1. A method of reducing the number of eosinophils in the human body, which consists in the fact that the specified subject is injected with a substance that binds to IL-5P, which includes (a) a fragment that specifically binds to IL-5P, and (b) an immunoglobulin Fc fragment .2. A method according to claim 1, wherein said substances that bind to IL-5P are antibodies. The method of claim 2, wherein said antibodies are monoclonal antibodies. The method of claim 3, wherein said antibodies are hybrid antibodies. The method of claim 3, wherein said antibodies are humanized antibodies. The method of claim 3, wherein said antibodies are human antibodies. The method of claim 1, wherein said fragment that specifically binds to IL-5P comprises the amino acid sequence of IL-5 or fragments thereof, variants including amino acid substitutions, or derivatives. The method of claim 7, wherein said fragment that specifically binds to IL-5P includes a non-functional variant of IL-5.9. The method of claim 1, wherein said substance that binds to IL-5P binds to the α-chain of IL-5P.10. The method of claim 1, wherein said immunoglobulin Fc fragment is modified to enhance effector function. The method of claim 1, wherein said immunoglobulin Fc fragment contains a reduced amount of fucose. The method of claim 11, wherein said immunoglobulin Fc fragment does not contain fucose. The method of claim 1, wherein said immunoglobulin Fc fragment comprises amino acid substitutions that result in increased effector function. The method of claim 1, wherein said amino acid substitutions include inserts in the Fc fragment of the following amino acid sequences: 332E, 239D and 330L, indicated by the EU index, p |
| priorityDate | 2007-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.